MedTrace Logo

TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors

NCT06088472 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-09-29

No results posted yet for this study

Summary

This is a single-center, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, NMA-LD chemotherapy , treatment and observation period, and follow-up period.

Conditions

  • Solid Tumors, Adult

Interventions

BIOLOGICAL

TIL injection

Autologous tumor infiltrating lymphocyte injection

Sponsors & Collaborators

  • Grit Biotechnology

    lead INDUSTRY

  • The Affiliated Hospital of Xuzhou Medical University

    collaborator OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-21
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06088472 on ClinicalTrials.gov